Biotech Values

[DewDiligence]

MNTA—That certainly is a long stretch [by Amphastar].

In what was the defining moment of the 31-minute session, one of the appellate judges rhetorically asked Amphastar’s lawyer whether Amphastar’s interpretation of the pre-FDA-approval safe harbor would render all drug-manufacturing patents worthless.

Legal decisions are never a sure thing, but I feel pretty good about MNTA’s case on the Lovenox injunction.